rf-fullcolor.png

 

August 11, 2025
by Jason Scott

Recon: Prasad returns FDA as CBER chief; FDA grants priority review for GSK’s gonorrhea antibiotic

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

In Focus: US
  • Vinay Prasad returns to the FDA, weeks after his ouster (STAT) (Reuters) (Politico) (Bloomberg)
  • In internal FDA town hall, employees raise concerns about staffing, impromptu expert meetings (STAT)
  • Exclusive: Medical journal rejects Kennedy's call for retraction of vaccine study (Reuters)
  • CureVac and GSK to receive money and royalties from BioNTech/Pfizer as part of mRNA patent settlement (Endpoints)
  • GSK's antibiotic gets FDA priority review for oral treatment of gonorrhoea (Reuters)
In Focus: International                                                                                                       
  • Swiss government to meet pharma firms to discuss US tariffs (Reuters)
  • EU4Health Boost For Orphan Devices And SMEs (MedTech Insight)
  • Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis (MedTech Insight)
  • Novo, Orsted Woes Make Danish Stock Benchmark the World’s Worst (Bloomberg)
Pharma & Biotech
  • Alnylam could be the next mega-cap biotech (STAT)
  • Medical journal rejects Kennedy's call for retraction of vaccine study (Reuters)
  • IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal (Reuters)
  • Novartis plans Sjögren’s disease filings as antibody passes two Phase 3 studies (Endpoints)
  • FDA restricts use of bluebird's gene therapy Skysona due to increased blood cancer risk (Endpoints)
  • Former Biotech Raising $1.5 Billion to Hoard Trump-Tied Token (Bloomberg)
Medtech
  • FDA Formally Rescinds the LDT Final Rule Following Defeat in Court (FDA Law Blog)
  • Apreo raises $130M for pivotal trial of emphysema device (MedTech Dive)
  • Boston Scientific updates instructions of devices linked to 17 deaths (MedTech Dive)
  • Tandem, Insulet monitoring CMS payment proposal for diabetes tech (MedTech Dive)
  • Zimmer Biomet Targets 2027 Launch For Semi-Autonomous Orthopedic Robot After Monogram Acquisition (MedTech Insight)
  • Survey Reveals Gaps In Medtech Compliance Processes (MedTech Insight)
  • Environmental Group Questions FDA’s Stance On PFAS In Medical Devices (MedTech Insight)
Food & Nutrition
  • Danone targets consumers taking weight loss drugs with new drink (Reuters)
  • Albertsons outlines defense against growing ingredients costs (Food Dive)
Government, Regulatory & Legal  
  • Exclusive: USPS blocks shipping of illicit vapes in boost for Big Tobacco (Reuters)
  • Trump’s firing of the Bureau of Labor Statistics commissioner puts crucial health data at risk (STAT)
  • CDC shaken after gunman attacks its headquarters (STAT)
  • Inside the research machine that helps UnitedHealth protect its Medicare profits (STAT)
  • Trump administration launches investigation into Harvard’s federally funded research patents (STAT)
  • As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims? (Reuters)
  • Updated: HHS official tasked with MAHA relations fired amid hasty rollout of mRNA contract cuts (Endpoints)
  • Telehealth Abortions Are Centered in Poor States With Few Options, Study Finds (Bloomberg)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.
 
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.